Sensus Healthcare, Inc. SRTS

Moby summary of Sensus Healthcare, Inc.'s Q2 2026 earnings call

BOCA RATON, Fla., August 13, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026.

BOCA RATON, Fla., July 30, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.

Sensus Healthcare’s fair value estimate has been trimmed from US$6.88 to US$5.75, putting a sharper spotlight on what analysts think the stock is worth today. That shift reflects a mix of optimism and caution, as recent research weighs the SRT-100/Vision platform and 2026 reimbursement changes against execution risk and timing. Read on to see how to interpret these updated targets and what to watch as the story continues to evolve. Stay updated as the Fair Value for Sensus Healthcare shifts...

Moby summary of Sensus Healthcare, Inc.'s Q1 2026 earnings call

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...